{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:39:47Z","timestamp":1792690787597,"version":"4.5.0"},"reference-count":200,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016606","name":"Riley Children's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL131093"],"award-info":[{"award-number":["R01 HL131093"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["P01 HL160472"],"award-info":[{"award-number":["P01 HL160472"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ymthe.2025.03.043","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T16:59:27Z","timestamp":1743094767000},"page":"2015-2034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Gene therapy for hemophilia\u00a0\u2013 From basic science to first approvals of \u201cone-and-done\u201d therapies"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7213-998X","authenticated-orcid":false,"given":"Roland W.","family":"Herzog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"High","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.03.043_bib1","first-page":"1","article-title":"Molecular basis of hemophilia","volume":"4","author":"Lozier","year":"1990","journal-title":"Hematol. Pathol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-12-394596-9.00006-8","article-title":"Animal models of hemophilia","volume":"105","author":"Sabatino","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.ymthe.2025.03.043_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1538-7836.2011.04369.x","article-title":"Gene therapy for haemophilia: a long and winding road","volume":"9","author":"High","year":"2011","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.043_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ymthe.2019.11.006","article-title":"A Molecular Revolution in the Treatment of Hemophilia","volume":"28","author":"Butterfield","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2022.12.001","article-title":"First hemophilia B gene therapy approved: More than two decades in the making","volume":"31","author":"Herzog","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/73464","article-title":"Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector","volume":"24","author":"Kay","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.03.043_bib7","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","article-title":"The state of cell and gene therapy in 2023","volume":"31","author":"Chancellor","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib8","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1182\/bloodadvances.2023011366","article-title":"Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A","volume":"7","author":"Agosti","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.043_bib9","first-page":"67","article-title":"Stable Factor IX expression and sustained reductions in factor IX use 8 years after gene therapy with CSL220 (Formerly AMT-060) in adults with hemophilia B","volume":"45","author":"Leebeek","year":"2025","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.ymthe.2025.03.043_bib10","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood-2023-186891","article-title":"Stable Therapeutic Transgenic FIX Levels for More Than 10 Years in Subjects with Severe Hemophilia B Who Received scAAV2\/8-LP1-Hfixco Adeno-Associated Virus Gene Therapy","volume":"142","author":"Reiss","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib11","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood-2021-150541","article-title":"Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy","volume":"138","author":"Samelson-Jones","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib12","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib13","first-page":"112","article-title":"A Multi-Year Follow-up Study of Fidanacogene Elaparvovec Gene Therapy for Hemophilia B","volume":"100","author":"Samelson-Jones","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib14","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib15","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib16","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-Associated Virus Gene Therapy for Hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib18","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/bloodadvances.2023010511","article-title":"Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec","volume":"8","author":"Anguela","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.043_bib19","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","article-title":"Roctavian gene therapy for hemophilia A","volume":"8","author":"Samelson-Jones","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.043_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/jvh.13915","article-title":"Integration and the risk of liver cancer-Is there a real risk?","volume":"31","author":"Kasimsetty","year":"2024","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.ymthe.2025.03.043_bib21","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib22","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/j.jtha.2024.07.012","article-title":"Adeno-associated viral vector integration: implications for long-term efficacy and safety","volume":"22","author":"Batty","year":"2024","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.043_bib23","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2741\/4324","article-title":"Gene therapy for hemophilia","volume":"20","author":"Rogers","year":"2015","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ymthe.2025.03.043_bib24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nm0397-306","article-title":"Recombinant adeno-associated virus for muscle directed gene therapy","volume":"3","author":"Fisher","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib25","doi-asserted-by":"crossref","first-page":"14082","DOI":"10.1073\/pnas.93.24.14082","article-title":"Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein","volume":"93","author":"Kessler","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.043_bib26","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1128\/jvi.70.11.8098-8108.1996","article-title":"Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector","volume":"70","author":"Xiao","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib27","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1073\/pnas.94.11.5804","article-title":"Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus","volume":"94","author":"Herzog","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.043_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ng0797-270","article-title":"Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors","volume":"16","author":"Snyder","year":"1997","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.03.043_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2003-05-1446","article-title":"Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1","volume":"103","author":"Arruda","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib30","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/hum.2008.161","article-title":"Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer","volume":"20","author":"Cooper","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib31","doi-asserted-by":"crossref","first-page":"10497","DOI":"10.1128\/JVI.76.20.10497-10502.2002","article-title":"Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector","volume":"76","author":"Mingozzi","year":"2002","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ymthe.2004.12.022","article-title":"Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models","volume":"11","author":"Davidoff","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib33","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib34","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: The Rubik's cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib35","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1182\/blood-2009-12-261156","article-title":"Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B","volume":"115","author":"Arruda","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib36","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2004-07-2908","article-title":"Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model","volume":"105","author":"Arruda","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/4743","article-title":"Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector","volume":"5","author":"Herzog","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/4751","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib39","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/mt.2009.159","article-title":"Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B","volume":"17","author":"Cao","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/mthe.2001.0441","article-title":"Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9","volume":"4","author":"Fields","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib41","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1089\/104303402760128513","article-title":"Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy","volume":"13","author":"Herzog","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/mthe.2001.0442","article-title":"Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation","volume":"4","author":"Herzog","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib43","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib44","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib45","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/MOH.0000000000000446","article-title":"Tolerance induction in hemophilia: innovation and accomplishments","volume":"25","author":"Sherman","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib47","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2014-02-554501","article-title":"Murine coagulation factor VIII is synthesized in endothelial cells","volume":"123","author":"Everett","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood-2015-12-684688","article-title":"Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in\u00a0vivo","volume":"128","author":"Pan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib49","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1182\/blood-2014-02-555151","article-title":"A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII","volume":"123","author":"Fahs","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib50","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood.V95.5.1594.005k34_1594_1599","article-title":"Sustained expression of human factor VIII in mice using a parvovirus-based vector","volume":"95","author":"Chao","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib52","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","article-title":"Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib53","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2003-01-0222","article-title":"Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib54","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1016\/j.jtha.2023.10.005","article-title":"Cellular stress and coagulation factor production: when more is not necessarily better","volume":"21","author":"Chen","year":"2023","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.043_bib55","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/j.ymthe.2022.10.004","article-title":"Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma","volume":"30","author":"Kapelanski-Lamoureux","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib56","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib57","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood.2021014735","article-title":"Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A","volume":"140","author":"Batty","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101205","article-title":"AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life","volume":"32","author":"Doshi","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","article-title":"Target-Cell-Directed Bioengineering Approaches for Gene Therapy of Hemophilia A","volume":"9","author":"Brown","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib62","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon Modification and PAMPs in Clinical AAV Vectors: The Tortoise or the Hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omtm.2021.11.005","article-title":"Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A","volume":"24","author":"Elkouby","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib64","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-0044-1790601","article-title":"Mice Engrafted with Human Liver Cells","volume":"44","author":"de Jong","year":"2024","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ymthe.2025.03.043_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-024-02539-y","article-title":"AAV vectors tested in perfused human livers","author":"Herzog","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-024-02523-6","article-title":"AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion","author":"Kim","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib67","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12875","article-title":"Selection and evaluation of clinically relevant AAV variants in a xenograft liver model","volume":"506","author":"Lisowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.043_bib68","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in\u00a0vivo targeting of transduced hepatocytes by capsid-specific CD8+ T\u00a0cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib69","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1006\/mthe.2001.0491","article-title":"Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males","volume":"4","author":"Arruda","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib70","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ymthe.2006.05.004","article-title":"Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B","volume":"14","author":"Jiang","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib71","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib72","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib73","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1172\/JCI36891","article-title":"Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors","volume":"119","author":"Pien","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.043_bib74","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib75","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ymthe.2005.09.009","article-title":"Identification of mouse AAV capsid-specific CD8+ T\u00a0cell epitopes","volume":"12","author":"Sabatino","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/hum.2007.001","article-title":"Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T\u00a0cells but does not render hepatocytes effective cytolytic targets","volume":"18","author":"Wang","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib77","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/mt.2011.81","article-title":"Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates","volume":"19","author":"Li","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.29","article-title":"AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes","volume":"2","author":"Hui","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib79","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/mt.2009.257","article-title":"Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction","volume":"18","author":"Finn","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib80","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib81","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib82","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.043_bib83","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.03.043_bib84","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib85","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.mt.6300355","article-title":"Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose","volume":"16","author":"Wu","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib86","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymthe.2025.03.043_bib88","first-page":"3331","article-title":"101HEMB01 Is a Phase 1\/2 Open-Label, Single Ascending Dose-Finding Trial of DTX101 (AAVrh10FIX) in Patients with Moderate\/Severe Hemophilia B That Demonstrated Meaningful but Transient Expression of Human Factor IX (hFIX)","volume":"130","author":"Pipe","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib89","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib90","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1182\/blood-2016-11-751040","article-title":"Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8(+) T\u00a0cells","volume":"129","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib91","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ymthe.2019.11.011","article-title":"Type I IFN Sensing by cDCs and CD4(+) T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8(+) T Cells","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CpG Depletion of Vector Genome on CD8(+) T Cell Responses in AAV Gene Therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib93","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ymthe.2023.11.029","article-title":"TLR9-independent CD8(+) T\u00a0cell responses in hepatic AAV gene transfer through IL-1R1-MyD88 signaling","volume":"32","author":"Kumar","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/v16101507","article-title":"Redundancy in Innate Immune Pathways That Promote CD8(+) T-Cell Responses in AAV1 Muscle Gene Transfer","volume":"16","author":"Li","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.043_bib95","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib96","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1016\/j.ymthe.2022.06.002","article-title":"Worldwide use of factor IX Padua for hemophilia B gene therapy","volume":"30","author":"Samelson-Jones","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib97","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2019000405","article-title":"Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants","volume":"5","author":"Samelson-Jones","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.043_bib98","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib99","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2012-05-432591","article-title":"Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice","volume":"120","author":"Cantore","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib100","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib101","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","article-title":"The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy","volume":"120","author":"Finn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib102","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib103","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.043_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib106","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2022.01.015","article-title":"Treatment-induced hemophilic thrombosis?","volume":"30","author":"Kaczmarek","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib107","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib108","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib109","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib111","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII Gene Transfer in Severe Hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib112","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib113","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.043_bib114","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/hae.15071","article-title":"Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.03.043_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial","volume":"8","author":"Leavitt","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.043_bib116","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib117","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41591-022-01751-0","article-title":"Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A","volume":"28","author":"Fong","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib118","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1016\/j.ymthe.2022.11.001","article-title":"Vector genome loss and epigenetic modifications mediate decline in transgene expression of AAV5 vectors produced in mammalian and insect cells","volume":"30","author":"Handyside","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtha.2024.12.038","article-title":"Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study","author":"Ozelo","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.043_bib120","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/hae.14936","article-title":"Long-term safety and efficacy outcomes of valoctocogene roxaparvovec gene transfer up to 6 years post-treatment","volume":"30","author":"Symington","year":"2024","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.03.043_bib121","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14818","article-title":"Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis","volume":"29","author":"Astermark","year":"2023","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.03.043_bib122","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.03.043_bib123","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2022007620","article-title":"The bleeding phenotype in people with nonsevere hemophilia","volume":"6","author":"Kloosterman","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.043_bib124","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/hae.15121","article-title":"A phase 1\/2 safety and efficacy study of TAK-754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials","volume":"31","author":"Chapin","year":"2025","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.03.043_bib125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1566523222666220914105729","article-title":"Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy","volume":"23","author":"Pipe","year":"2023","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib126","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1182\/blood-2021-148661","article-title":"First-in-Human Dose-Finding Study of AAVhu37 Vector-Based Gene Therapy: BAY 2599023 Has Stable and Sustained Expression of FVIII over 2 Years","volume":"138","author":"Pipe","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib127","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A","volume":"385","author":"George","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib128","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtm.2021.12.004","article-title":"Molecular analysis of AAV5-hFVIII-SQ vector-genome-processing kinetics in transduced mouse and nonhuman primate livers","volume":"24","author":"Sihn","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib129","first-page":"20","article-title":"Stable expression of factor VIII over 5 years following adeno-associated viral vector-mediated gene transfer in participants with severe haemophilia a using a novel human factor VIII variant","volume":"30","author":"Chowdary","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2025.03.043_bib130","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1038\/s41467-024-51296-8","article-title":"Pre-clinical evaluation of an enhanced-function factor VIII variant for durable hemophilia A gene therapy in male mice","volume":"15","author":"Sternberg","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.043_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib132","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.2023023275","article-title":"Coagulation factor VIII: biological basis of emerging hemophilia A therapies","volume":"144","author":"Samelson-Jones","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib133","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/blood-2023-180803","article-title":"GO-8: Stable Expression of Factor VIII over 5 Years Following Adeno-Associated Gene Transfer in Subjects with Hemophilia a Using a Novel Human Factor VIII Variant","volume":"142","author":"Chowdary","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib134","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib135","first-page":"290","article-title":"Factor VIII trafficking to CD4+ T\u00a0cells shapes its immunogenicity and requires several types of antigen-presenting cells","volume":"142","author":"Kaczmarek","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib136","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.ymthe.2022.07.005","article-title":"IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice","volume":"30","author":"Butterfield","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib137","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/jth.13543","article-title":"Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A","volume":"15","author":"Nguyen","year":"2017","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.043_bib138","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89371","article-title":"Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models","volume":"1","author":"Siner","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.03.043_bib139","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.omtm.2020.10.013","article-title":"Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency","volume":"19","author":"Cao","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib140","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A","volume":"17","author":"Doering","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib141","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2023-178106","article-title":"Evolution Directed Gene Engineering (EDGE) Identifies Single Amino Acid Substitutions in FVIII with Six-Fold Increased in\u00a0Vitro and In\u00a0Vivo Activity","volume":"142","author":"Van Gorder","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib142","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy","volume":"12","author":"Samelson-Jones","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib143","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in\u00a0vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.043_bib144","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jtha.2023.05.011","article-title":"A review of the rationale for gene therapy for hemophilia A with inhibitors: one-shot tolerance and treatment?","volume":"21","author":"Valentino","year":"2023","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2025.03.043_bib145","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ymthe.2017.02.014","article-title":"The Balance between CD8(+) T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose","volume":"25","author":"Kumar","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037671","article-title":"Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy","volume":"7","author":"Sack","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.03.043_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2017.12.002","article-title":"Liver induced transgene tolerance with AAV vectors","volume":"342","author":"Keeler","year":"2019","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib148","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ymthe.2016.11.009","article-title":"Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce","volume":"25","author":"Herzog","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib149","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib150","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.2022016530","article-title":"Immune complications and their management in inherited and acquired bleeding disorders","volume":"140","author":"Arruda","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib151","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A","volume":"11","author":"Samelson-Jones","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib152","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/bloodadvances.2024013000","article-title":"Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors","volume":"9","author":"Young","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2025.03.043_bib153","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ymthe.2024.03.016","article-title":"Immune tolerance induction by hepatic gene transfer: First-in-human evidence","volume":"32","author":"Kaczmarek","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib154","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib156","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1089\/hum.2021.287","article-title":"Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A","volume":"33","author":"Klamroth","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib157","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"Li","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib158","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/jmv.23818","article-title":"The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals","volume":"86","author":"Mimuro","year":"2014","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib159","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib160","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2019.05.014","article-title":"Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors","volume":"14","author":"Kruzik","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib161","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/gt.2014.103","article-title":"AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy","volume":"22","author":"Thwaite","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib162","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction","volume":"9","author":"Fitzpatrick","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib163","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib164","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib165","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1089\/hum.2011.031","article-title":"Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors","volume":"22","author":"Wang","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib166","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","article-title":"Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A","volume":"32","author":"Long","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib167","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1128\/JVI.73.2.939-947.1999","article-title":"Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses","volume":"73","author":"Bantel-Schaal","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib168","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1128\/JVI.00867-13","article-title":"Structural insights into adeno-associated virus serotype 5","volume":"87","author":"Govindasamy","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib169","doi-asserted-by":"crossref","DOI":"10.3390\/v13010101","article-title":"Completion of the AAV Structural Atlas: Serotype Capsid Structures Reveals Clade-Specific Features","volume":"13","author":"Mietzsch","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2025.03.043_bib170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/hae.14530","article-title":"Gene therapy - are we ready now?","volume":"28","author":"Kaczmarek","year":"2022","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.03.043_bib171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymthe.2024.11.026","article-title":"Second gene therapy for hemophilia B approved: More answers or questions?","volume":"33","author":"Kaczmarek","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib172","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.ymthe.2024.05.005","article-title":"Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques","volume":"32","author":"Pekrun","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib173","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/hum.2022.176","article-title":"Characterization of a Bioengineered AAV3B Capsid Variant with Enhanced Hepatocyte Tropism and Immune Evasion","volume":"34","author":"Rana","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib174","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/mt.2016.61","article-title":"Superior In\u00a0vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid","volume":"24","author":"Vercauteren","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib175","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.omtm.2021.08.001","article-title":"Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette","volume":"23","author":"Kumar","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib176","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.omtm.2020.05.001","article-title":"Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates","volume":"17","author":"Samelson-Jones","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib177","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ymthe.2020.05.004","article-title":"When Immune Suppression Goes Wrong","volume":"28","author":"Yamada","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101195","article-title":"Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74","volume":"32","author":"Potter","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101216","article-title":"B cell focused transient immune suppression protocol for efficient AAV readministration to the liver","volume":"32","author":"Rana","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib180","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/bph.17458","article-title":"Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review","volume":"182","author":"Topouzis","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2025.03.043_bib181","doi-asserted-by":"crossref","first-page":"e63277","DOI":"10.1002\/ajmg.a.63277","article-title":"Exploring the Low Uptake of Gene Therapy in Hemophilia","volume":"194","year":"2024","journal-title":"Am. J. Med. Genet. A."},{"key":"10.1016\/j.ymthe.2025.03.043_bib182","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/hae.14867","article-title":"Delivery of gene therapy in haemophilia treatment centres in the United States: Practical aspects of preparedness and implementation","volume":"29","author":"Pipe","year":"2023","journal-title":"Haemophilia."},{"key":"10.1016\/j.ymthe.2025.03.043_bib183","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1038\/s41467-023-39986-1","article-title":"Transplanting FVIII\/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity","volume":"14","author":"Rodriguez","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.043_bib184","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/hum.2018.137","article-title":"Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A","volume":"29","author":"Doering","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib185","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A","volume":"392","author":"Srivastava","year":"2025","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib186","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2015-07-607937","article-title":"Megakaryocyte- and megakaryocyte precursor-related gene therapies","volume":"127","author":"Wilcox","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib187","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.omtm.2018.01.011","article-title":"Platelet-Targeted Gene Therapy for Hemophilia","volume":"9","author":"Shi","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.03.043_bib188","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI28416","article-title":"Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies","volume":"116","author":"Shi","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.03.043_bib189","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/blood-2003-05-1519","article-title":"Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment","volume":"102","author":"Yarovoi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib190","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMc2415164","article-title":"Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History","volume":"392","author":"Eapen","year":"2025","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib191","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa2405541","article-title":"Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"391","author":"Duncan","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.03.043_bib192","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in\u00a0vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib193","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature10177","article-title":"In\u00a0vivo genome editing restores haemostasis in a mouse model of haemophilia","volume":"475","author":"Li","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.03.043_bib194","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.03.043_bib195","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood-2024-208135","article-title":"Site-specific insertion of factor VIII gene results in durable factor VIII expression in nonhuman primates","volume":"144","author":"Brooks","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib196","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2021-154505","article-title":"A Novel Type V CRISPR System with Potential for Genome Editing in the Liver","volume":"138","author":"Cost","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib197","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41467-021-26830-7","article-title":"Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models","volume":"12","author":"Hakim","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.03.043_bib198","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2023-189784","article-title":"Effective Gene Therapy for Hemophilia a: Novel Re-Dosable Non-Viral Formulation That Provides Stable, and Durable FVIII Expression with Improved Tolerability","volume":"142","author":"Truong","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.03.043_bib199","first-page":"A28","article-title":"A cell-targeted lipid nanoparticle technology with enhanced cell selectivity for in\u00a0vivo DNA delivery","volume":"35","author":"Stanton","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.03.043_bib200","doi-asserted-by":"crossref","first-page":"25931","DOI":"10.1182\/blood-2024-208733","article-title":"Become-9: A Phase 1\/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B","volume":"144","author":"Pipe","year":"2024","journal-title":"Blood"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625002175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:38:42Z","timestamp":1792687122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625002175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":200,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525001625002175"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.043","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for hemophilia\u00a0\u2013 From basic science to first approvals of \u201cone-and-done\u201d therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.03.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}